Avalon Globocare Corp Stock Price, News & Analysis

Avalon GloboCare (NASDAQ: ALBT) has partnered with SpecialtyHealth to enhance the BrAce 4 Impact Challenge (B4IC) using their KetoAir™ breathalyzer. The collaboration, launched on April 1, 2024, integrates SpecialtyHealth into Avalon's Zero to Keto Affiliate Marketing Program and B4IC Series.

The program combines Pounds Transformation's 4-week diet program with SpecialtyHealth's 'Famous Police Panel' wellness initiatives, targeting police chiefs across multiple states. The KetoAir™ device, FDA-registered (number: 3026284320), measures breath acetone concentration to track ketosis levels through nano-sensor technology.

This partnership focuses on supporting law enforcement officers in maintaining their health goals through real-time ketone monitoring. The device's pocket-sized design allows officers to check their ketone levels between shifts, providing immediate feedback and accountability in their wellness journey.

Avalon GloboCare (NASDAQ: ALBT) has secured a patent in China for its CAR-T and CAR-NK cell technology, valid for 20 years from April 4, 2025. The patent, titled 'Artificial Immunosurveillance Chimeric Antigen Receptor and Cells Expressing the Same,' was granted by the China National Intellectual Property Administration under No. CN 114502188 B.

Co-developed with Hong Kong-based Arbele , the technology features a bispecific Anti-CD19xCD22 CAR design targeting both CD19 and CD22 antigens to reduce tumor escape risk, and a localized cytokine induction mechanism to enhance CAR cell performance. The patent complements existing protections in the U.S. and other PCT territories, strengthening Avalon's global intellectual property portfolio in cell-based immunotherapy.

Avalon GloboCare (NASDAQ: ALBT) has partnered with Pounds Transformation Clinics to launch the 'BrAce 4 Impact Challenge Series,' featuring their KetoAir™ breathalyzer devices. The partnership includes placing KetoAir devices on consignment at three Connecticut locations.

Following a successful pilot program ending March 18, 2025, the first official challenge begins April 1, 2025. The KetoAir device, FDA-registered (No. 3026284320), measures breath acetone concentration to track ketosis status through nano-sensor technology, accessible via Apple App Store and Google Play Store.

Early results show promising outcomes, with pilot participants reporting significant weight loss success while maintaining BrAce readings around 12ppm. Pounds Transformation plans to initiate new challenges every six weeks, supported by dedicated coaches for daily participant guidance.

Avalon GloboCare (NASDAQ: ALBT) has announced a definitive merger agreement with YOOV, a leading business AI automation solutions provider. The merged entity will operate as YOOV and trade under the ticker 'YOOV' on Nasdaq, pending approval.

YOOV demonstrated strong financial performance with unaudited revenue of $45.7 million and net income of $3.4 million for calendar year 2024, compared to $28.7 million revenue and $2.4 million net loss in 2023, representing 59.1% annual revenue growth.

Post-merger ownership structure will see YOOV shareholders holding approximately 97.5-97.8% of the combined company, while Avalon shareholders will retain 2.2-2.5%. The transaction is expected to close in Q3 2025, subject to stockholder approval. Phil Wong will serve as Chairman, CEO, and President of the combined company, with a seven-member board comprising five YOOV and two Avalon designees.

Avalon GloboCare (NASDAQ: ALBT) has received a Notice of Allowance from China's National Intellectual Property Administration for patent AVAR1901CN, co-developed with Arbele The patent covers innovative CAR-T and CAR-NK cell technology, extending Avalon's intellectual property beyond the U.S. and PCT territories.

The technology features a bispecific Anti-CD19xCD22 CAR design targeting both CD19 and CD22 antigens to minimize tumor escape risk. It also includes a localized cytokine induction system that enhances CAR cell effectiveness and activates anti-tumor immune responses specifically upon tumor engagement.

According to CEO David Jin, this platform technology aims to provide practical, cost-effective solutions for point-of-care cancer treatment, potentially improving accessibility and patient outcomes globally.

Avalon GloboCare (NASDAQ: ALBT), a precision diagnostics and laboratory services developer, has received notice from Nasdaq on November 19, 2024, confirming its regained compliance with the exchange's minimum bid price requirement under Rule 5550(a)(2). The company's CEO, David Jin, emphasized their commitment to shareholders and corporate governance, stating their continued focus on creating sustainable long-term value for both shareholders and stakeholders.

Avalon GloboCare (NASDAQ: ALBT) has launched the 'BrAce for Impact' affiliate marketing program for KetoAir™, an AI-enabled breathalyzer device for ketogenic health monitoring. The program, developed following demand from recent health conferences, offers affiliates discount codes and commissions on sales.

The initiative provides marketing materials and brand resources to affiliates, targeting metabolic coaches, podcasters, health authors, and influencers. KetoAir™, FDA-registered (No. 3026284320), measures breath acetone concentration using nano-sensor technology to assess ketosis status, with companion apps available on both Apple and Google platforms.

Avalon GloboCare (NASDAQ: ALBT) has appointed Dr. Charles Cavo to its Scientific and Clinical Advisory Board to support the development of KetoAir™, a handheld breathalyzer for ketogenic health monitoring. Dr. Cavo, co-founder and CMO of Pounds Transformation, brings expertise in obesity medicine and bariatric care. KetoAir™ measures Breath Acetone Concentration (BrAce) as a biomarker for ketosis, offering a non-invasive alternative to blood and urine testing. The device aims to support weight management and conditions like diabetes by providing real-time feedback on ketosis levels.

Avalon GloboCare (NASDAQ: ALBT) has entered into a memorandum of understanding with Qi Diagnostics to explore co-developing a VOC nanosensor-based cannabis breathalyzer. The MOU grants Avalon a 120-day exclusivity period to negotiate a definitive agreement. If successful, the collaboration would focus on developing a prototype for detecting cannabis, leveraging Avalon's regulatory expertise and experience with clinical trials. The project aims to address point-of-care testing needs in law enforcement and workplace safety. However, there is no guarantee that a definitive agreement will be reached during the exclusivity period.